✨ Free AI Report
9 Meters Biopharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research 9 Meters Biopharma, Inc.
Company Research

9 Meters Biopharma, Inc.: Business Overview, Financials & Competitive Analysis

9 Meters Biopharma, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Ceased operations with no active pipeline—investment thesis invalidated. The company has ceased operations, indicating failed commercialization efforts, likely capital constraints, and inability to advance its clinical pipeline. Stock price has declined significantly, reaching penny stock status with delisting concerns.

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

2/ 10Challenged

Cyborg Score thesis

Ceased operations with no active pipeline—investment thesis invalidated....

Read the full analyst-debate transcript →
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 16, 2026
AI-Generated Research
30+ Page Report

Get the Latest 9 Meters Biopharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for 9 Meters Biopharma, Inc.

AskCyborg analysts argue the bull and bear cases for 9 Meters Biopharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
9 Meters Biopharma, Inc. OverviewStrategic ProfileCompetitive LandscapeKey facts
Get Interactive Report Freeor start reading below

9 Meters Biopharma, Inc. Overview

Pro stress-test →

9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.

Strategic Profile

Pro stress-test →

The company previously focused on developing therapies including vurolenatide for short bowel syndrome and GIP antagonist NM-136 for obesity. Its pipeline-focused business model and clinical-stage status made it dependent on successful development milestones and funding.

Competitive Landscape

Pro stress-test →

As a ceased-stage company, 9 Meters no longer competes in the market. Previously, it competed against established GI therapeutics developers and obesity drug manufacturers.

Key facts

Headquarters: Raleigh, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on 9 Meters Biopharma, Inc..

  • Company ceased operations after struggling with pipeline advancement and funding
  • Stock declined 90% over the prior year period with delisting concerns
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Compare 9 Meters Biopharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account
NEW · MCP server

Ask your AI assistant about 9 Meters Biopharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare 9 Meters Biopharma, Inc. and its top competitor on Cyborg Score”
“What did 9 Meters Biopharma, Inc. do this quarter?”
“Is 9 Meters Biopharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does 9 Meters Biopharma, Inc. do?+
9 Meters Biopharma was a clinical-stage biopharmaceutical company focused on treatments for rare digestive diseases and gastrointestinal conditions with unmet needs. The company has ceased operations.
What is 9 Meters Biopharma, Inc.'s Cyborg Score?+
9 Meters Biopharma, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are 9 Meters Biopharma, Inc.'s main competitors?+
The full competitive landscape for 9 Meters Biopharma, Inc. is in the AskCyborg report.
How can I get the full 9 Meters Biopharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the 9 Meters Biopharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track 9 Meters Biopharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual